216 related articles for article (PubMed ID: 10801874)
21. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein.
Requena JR; Fu MX; Ahmed MU; Jenkins AJ; Lyons TJ; Baynes JW; Thorpe SR
Biochem J; 1997 Feb; 322 ( Pt 1)(Pt 1):317-25. PubMed ID: 9078279
[TBL] [Abstract][Full Text] [Related]
22. Pyridoxamine inhibits maillard reactions in diabetic rat lenses.
Padival S; Nagaraj RH
Ophthalmic Res; 2006; 38(5):294-302. PubMed ID: 16974131
[TBL] [Abstract][Full Text] [Related]
23. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine.
Chetyrkin SV; Mathis ME; Ham AJ; Hachey DL; Hudson BG; Voziyan PA
Free Radic Biol Med; 2008 Apr; 44(7):1276-85. PubMed ID: 18374270
[TBL] [Abstract][Full Text] [Related]
24. Novel inhibitors of glycation and AGE formation.
Rahbar S
Cell Biochem Biophys; 2007; 48(2-3):147-57. PubMed ID: 17709884
[TBL] [Abstract][Full Text] [Related]
25. Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products.
Curtis TM; Hamilton R; Yong PH; McVicar CM; Berner A; Pringle R; Uchida K; Nagai R; Brockbank S; Stitt AW
Diabetologia; 2011 Mar; 54(3):690-8. PubMed ID: 21116609
[TBL] [Abstract][Full Text] [Related]
26. In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques.
Imanaga Y; Sakata N; Takebayashi S; Matsunaga A; Sasaki J; Arakawa K; Nagai R; Horiuchi S; Itabe H; Takano T
Atherosclerosis; 2000 Jun; 150(2):343-55. PubMed ID: 10856526
[TBL] [Abstract][Full Text] [Related]
27. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways.
Booth AA; Khalifah RG; Todd P; Hudson BG
J Biol Chem; 1997 Feb; 272(9):5430-7. PubMed ID: 9038143
[TBL] [Abstract][Full Text] [Related]
28. Study of pyridoxamine against glycation and reactive oxygen species production in human serum albumin as model protein: An in vitro & ex vivo approach.
Abdullah KM; Qais FA; Ahmad I; Hasan H; Naseem I
Int J Biol Macromol; 2018 Dec; 120(Pt B):1734-1743. PubMed ID: 30268752
[TBL] [Abstract][Full Text] [Related]
29. Inhibition effect of pyridoxamine on lipid hydroperoxide-derived modifications to human serum albumin.
Lee SH; Matsunaga A; Oe T
PLoS One; 2018; 13(4):e0196050. PubMed ID: 29672562
[TBL] [Abstract][Full Text] [Related]
30. Chemical modification of proteins during peroxidation of phospholipids.
Januszewski AS; Alderson NL; Jenkins AJ; Thorpe SR; Baynes JW
J Lipid Res; 2005 Jul; 46(7):1440-9. PubMed ID: 15805546
[TBL] [Abstract][Full Text] [Related]
31. Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat.
Muellenbach EA; Diehl CJ; Teachey MK; Lindborg KA; Archuleta TL; Harrell NB; Andersen G; Somoza V; Hasselwander O; Matuschek M; Henriksen EJ
Metabolism; 2008 Oct; 57(10):1465-72. PubMed ID: 18803954
[TBL] [Abstract][Full Text] [Related]
32. Effect and mechanism of pyridoxamine on the lipid peroxidation and stability of polyunsaturated fatty acids in beef patties.
Wong D; Hu X; Tao N; Wang X; Wang M
J Sci Food Agric; 2016 Aug; 96(10):3418-23. PubMed ID: 26538517
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Cameron NE; Gibson TM; Nangle MR; Cotter MA
Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
[TBL] [Abstract][Full Text] [Related]
34. Kavalactones, a novel class of protein glycation and lipid peroxidation inhibitors.
Upadhyay A; Tuenter E; Ahmad R; Amin A; Exarchou V; Apers S; Hermans N; Pieters L
Planta Med; 2014 Aug; 80(12):1001-8. PubMed ID: 25098935
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of metformin and pyridoxamine in the formation of early, intermediate and advanced glycation end-products.
Ahmad S; Shahab U; Baig MH; Khan MS; Khan MS; Srivastava AK; Saeed M; Moinuddin
PLoS One; 2013; 8(9):e72128. PubMed ID: 24023728
[TBL] [Abstract][Full Text] [Related]
36. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
37. Formation of N(epsilon)-(carboxymethyl)lysine and loss of lysine in casein glucose-fatty acid model systems.
Lima M; Assar SH; Ames JM
J Agric Food Chem; 2010 Feb; 58(3):1954-8. PubMed ID: 20030411
[TBL] [Abstract][Full Text] [Related]
38. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors.
Picard S; Parthasarathy S; Fruebis J; Witztum JL
Proc Natl Acad Sci U S A; 1992 Aug; 89(15):6876-80. PubMed ID: 1495978
[TBL] [Abstract][Full Text] [Related]
39. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.
Reddy S; Bichler J; Wells-Knecht KJ; Thorpe SR; Baynes JW
Biochemistry; 1995 Aug; 34(34):10872-8. PubMed ID: 7662668
[TBL] [Abstract][Full Text] [Related]
40. The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect.
Adrover M; Vilanova B; Frau J; Muñoz F; Donoso J
Bioorg Med Chem; 2008 May; 16(10):5557-69. PubMed ID: 18434162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
